A recent study found that the majority of interventional phase 3 trials lacked a clear definition of high-risk multiple myeloma, and many patients were missing important data for risk stratification.

Cynthia Wilson, who is executive director of CIIN, and John Wilson, its president, are meeting with representatives for senators Christopher Bond (R-Mo.), Max Baucus (D-Mont.), Jon Kyl (R-Ariz.) and ...